Skip to main content

Advertisement

SpringerLink
Log in

Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the efficacy and toxicity of cetuximab and pemetrexed as the second-line treatment for advanced esophageal cancer patients, who had undergone treatment with the standard cisplatin and 5-FU regimens.

Methods

A total of 29 patients accepted this treatment. Cetuximab was administered at an initial dose of 400 mg/m2 IV followed by weekly doses of 250 mg/m2 IV, whereas pemetrexed 500 mg/m2 was administered on day 1 every 3 weeks.

Results

Twelve patients (41.4 %) presented PR, ten (34.5 %) had SD, and seven (24.1 %) had PD. The response rate was 41.4 %. The median PFS was 4.5 months (95 % CI 4.1–4.9), and the median OS was 9.4 months (95 % CI 8.4–10.5). The expression levels of serum miR-335 were determined, and the subsequent analysis suggested that PFS was significantly different between the patients with higher level of serum miR-335 and those with low level of serum miR-335. The former had a PFS of 4.9 months (95 % CI 4.2–5.7) and the latter 4.1 months (95 % CI 3.7–4.5) (log rank = 0.025). None of the patients experienced grade 4 toxicity. Twenty-four patients presented rash.

Conclusions

A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tang WR, Fang JY, Wu KS et al (2014) Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012. Asian Pac J Cancer Prev 15:6929–6934

    Article  PubMed  Google Scholar 

  2. Hofstetter W, Swisher SG, Correa AM et al (2002) Treatment outcomes of resected esophageal cancer. Ann Surg 236:376–384

    Article  PubMed Central  PubMed  Google Scholar 

  3. A-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442

    Article  Google Scholar 

  4. Lorenzen S, Schuster T, Porschen R et al (2009) Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20:1667–1673

    Article  CAS  PubMed  Google Scholar 

  5. Thallinger CM, Raderer M, Hejna M (2011) Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29:4709–4714

    Article  CAS  PubMed  Google Scholar 

  6. Liao Z, Cox JD, Komaki R (2007) Radiochemotherapy of esophageal cancer. J Thorac Oncol 2:553–568

    Article  PubMed  Google Scholar 

  7. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  PubMed  Google Scholar 

  8. Safran H, Suntharalingam M, Dipetrillo T et al (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391–395

    Article  CAS  PubMed  Google Scholar 

  9. Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404–417

    Article  CAS  PubMed  Google Scholar 

  10. Tian GY, Miu M, Huang XE (2014) Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev 15:8475–8478

    Article  PubMed  Google Scholar 

  11. Li BS, Gong HY, Huang W et al (2011) Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 24(4):251–257

    Article  PubMed  Google Scholar 

  12. Jatoi A, Soori G, Foster NR et al (2010) Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol 5:1994–1998

    Article  PubMed  Google Scholar 

  13. Katipamula R, Jatoi A, Foster NR et al (2008) Pemetrexed, carboplatin, and concomitant radiation followed by surgery for locally advanced esophageal cancer: results of a planned interim toxicity analysis of North Central Cancer Treatment Group Study N044E. Clin Med Oncol 2:223–225

    PubMed Central  CAS  PubMed  Google Scholar 

  14. Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419–423

    Article  CAS  PubMed  Google Scholar 

  15. Syrigos KN, Zalonis A, Kotteas E et al (2008) Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev 27:273–288

    Article  CAS  PubMed  Google Scholar 

  16. Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959

    Article  CAS  PubMed  Google Scholar 

  17. Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272

    Article  CAS  PubMed  Google Scholar 

  18. Shirakawa T, Kato K, Nagashima K et al (2014) A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol 74(6):1207–1215

    Article  CAS  PubMed  Google Scholar 

  19. Jin J, Xu X, Wang F et al (2009) Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 4(8):1017–1021

    Article  PubMed  Google Scholar 

  20. Airoldi M, Cortesina G, Giordano C et al (2003) Docetaxel and vinorelbine an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 20(1):19–24

    Article  CAS  PubMed  Google Scholar 

  21. Li X, Lin W, Wang H et al (2013) Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. Med Oncol 30(4):746

    Article  PubMed  Google Scholar 

  22. Akutsu Y, Kono T, Uesato M et al (2013) S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. Oncology 84(5):305–310

    Article  CAS  PubMed  Google Scholar 

  23. Chan JA, Blaszkowsky LS, Enzinger PC et al (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 6:1367–1373

    Article  Google Scholar 

  24. Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparitieson premature cancer deaths. CA Cancer J Clin 61:212–236

    Article  PubMed  Google Scholar 

  25. Lordick F (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):490–499

    Article  CAS  PubMed  Google Scholar 

  26. Janjigian YY (2012) Phase II trial of cetuximab plus cisplatin and irinotecanin patients with cisplatin and irinotecan-refractory metastatic esopha-gogastric cancer. Am J Clin Oncol 37(2):126–130

    Article  Google Scholar 

  27. Waddell T (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):481–489

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

    Article  CAS  PubMed  Google Scholar 

  29. Hummel R, Watson DI, Smith C et al (2011) Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 15:429–438

    Article  PubMed  Google Scholar 

  30. Imanaka Y, Tsuchiya S, Sato F et al (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 56:270–276

    Article  CAS  PubMed  Google Scholar 

  31. Lynam-Lennon N, Reynolds JV, Marignol L et al (2012) MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl) 90:1449–1458

    Article  CAS  Google Scholar 

  32. Zhang BJ, Gong HY, Zheng F et al (2014) Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 7(9):6213–6218

    PubMed Central  PubMed  Google Scholar 

  33. Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, Stallings RL (2012) MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis 33:976–985

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Tomé M, López-Romero P, Albo C, Sepúlveda JC, Fernández-Gutiérrez B, Dopazo A, Bernad A, González MA (2011) miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 18:985–995

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported in part by 81301936 from National Nature Science Foundation of China.

Author information

Author notes

    Authors and Affiliations

    1. Department of Medical Oncology, Shan Dong Tumor Hospital, 440 Jiyan Road, Jinan, Shandong, People’s Republic of China

      Jing Tian, Ming Shang, Sheng-Bin Shi, Yong Han & Jun Xu

    Authors
    1. Jing Tian
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ming Shang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Sheng-Bin Shi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Yong Han
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jun Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Sheng-Bin Shi.

    Ethics declarations

    Conflict of interest

    No conflicts of interest exist for any of the authors of this paper.

    Additional information

    Jing Tian and Ming Shang have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Tian, J., Shang, M., Shi, SB. et al. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 76, 829–834 (2015). https://doi.org/10.1007/s00280-015-2854-0

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00280-015-2854-0

    Keywords

    Search

    Navigation